Early FDA Approval of Kaleo's Evzio Auto Injector
Thursday, April 3, 2014
Today, the FDA approved Evzio (naloxone autoinjector), a product of Richmond based, Kaleo (formerly Intelliject). Evzio is a prescription treatment that can be used by family members or caregivers to treat a person known or suspected to have had an opioid overdose. Evzio (naloxone hydrochloride injection) rapidly delivers a single dose of the drug naloxone via a hand-held auto-injector that can be carried in a pocket or stored in a medicine cabinet.
For more than a decade, the U.S. Food and Drug Administration has been
working to address the important public health problems associated with
the misuse, abuse, addiction and overdose of opioid analgesics, while at
the same time working to ensure continued access to effective and
appropriate medications for millions of Americans currently suffering
Evzio is injected into the muscle (intramuscular) or under the skin (subcutaneous). Once turned on, the device provides verbal instruction to the user describing how to deliver the medication, similar to automated defibrillators. Family members or caregivers should become familiar with all instructions for use before administering to known or suspected persons to have had an opioid overdose. Family members or caregivers should also become familiar with the steps for using Evzio and practice with the trainer device, which is included along with the delivery device, before it is needed.
Reflecting the FDA’s commitment to encouraging important new therapies, the FDA’s review of Evzio was granted priority status, and the application was reviewed by the FDA in just 15 weeks.
This product is the first auto-injector designed to rapidly reverse the overdose of either prescription or illicit opioids. While the larger goal is to reduce the need for products like these by preventing opioid addiction and abuse, they are extremely important innovations that will help to save lives.
To read the FDA's statement on prescription opioid abuse click here.